Pfizer is projected to report Q2 2026 revenue of $14.43 billion and adjusted EPS of $0.68, as the stock trades near $25.10 relative to a $28.75 analyst target.
Investors are primarily focused on the growth of the oncology portfolio and the successful integration of Seagen assets following recent regulatory wins. While legacy COVID-related sales continue to face year-over-year declines, the market is looking for evidence that new products like Padcev can offset upcoming patent expirations.
Additionally, updates on the Phase 3 obesity candidate berobenatide and the progress of the company's multi-billion dollar cost-alignment program will be critical for forward sentiment.